Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced this morning that it would be halting its Phase 3 study of its Tonmya drug, which caused its stock price to drop in dramatic fashion. After its twelve-week trial, Tonmya, a drug that treats military-related post-traumatic stress disorder (PTSD), showed “inadequate separation from placebo.”
What is happening with Tonix Pharmaceuticals Holding Corp (TMP) stock?
The Tonix Pharmaceuticals Holding Corp.stock price fell by -4.42%on the last day (Friday, 10th Dec 2021) from $0.40to $0.38. and has now fallen 3 days in a row. During the day the stock fluctuated 7.29%from a day low at $0.38to a day high of $0.41. The price has fallen in 7 of the last 10 days and is down by -24.2%for this period.
What does Tonix's reverse stock split mean for investors?
Reverse stock splits aren't a sign that things are going well for a company. That's certainly the case for Tonix. The company's board of directors approved the 1-for-32 reverse stock split to boost Tonix's share price. This move was needed to meet the $1 minimum bid requirement for the stock to remain listed on the Nasdaq Stock Market.
Did TNX-102 SL meet its primary endpoint?
CEO Seth Lederman said that the company was "surprised and disappointed" by the interim analysis findings. That's understandable, especially considering that TNX-102 SL met the primary endpoint of a previous late-stage study that was similar in design.
What are the products of TNX-102 SL?
The company's lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of fibromyalgia; and Phase ... Read more Golden Star Signal This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
Is TNXP stock a good buy?
TNXP has an average analyst recommendation of Strong Buy. The company has an average price target of $1.37. TNXP has an Overall Score of 24.
What is the future of TNXP?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) The 2 analysts offering 12-month price forecasts for Tonix Pharmaceuticals Holding Corp have a median target of 53.00, with a high estimate of 96.00 and a low estimate of 10.00. The median estimate represents a +2,072.13% increase from the last price of 2.44.
Will TNXP go up?
On average, analysts forecast that TNXP's EPS will be -$6.73 for 2023, with the lowest EPS forecast at -$7.99, and the highest EPS forecast at -$5.48. In 2024, TNXP's EPS is forecast to hit -$5.12 (min: -$5.12, max: -$5.12).
Is TNXP going to reverse split?
(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 17, 2022.
Who owns TNXP stock?
STATE STREET CORPInstitutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission....New and Sold Out Positions.OWNER NAMESTATE STREET CORPSHARES HELD232,691CHANGE (SHARES)23,891CHANGE (%)11.442%VALUE (IN 1,000S)$54714 more columns
Why did TNXP stock drop in 2018?
Brittany Meiling. After scoring two promising FDA designations on its lead drug, tiny Tonix Pharmaceuticals is aborting its late-stage study in PTSD due to lousy results — nearly flat-lining the company's stock Friday morning.
When did TNXP go public?
It was listed on the NASDAQ exchange in 2013 under the symbol TNXP. Ernest Mario, a scientist and former CEO of Glaxo Holdings Inc, served on the board of Tonix in the past.
How many employees does tonix Pharma have?
Compare TNXP With Other StocksTonix Pharmaceuticals Holding Annual Number of Employees2021732020262019162018129 more rows
Will CEI stock go up?
Based on the algorithm-based CEI price prediction from Wallet Investor as of 22 March, the price of Camber Energy in the near term could rise to $1.14 per share by 4 April 2022.
How many shares of TNXP are there?
Share StatisticsAvg Vol (3 month) 31.9MShares Outstanding 518.74MImplied Shares Outstanding 6N/AFloat 818.73M% Held by Insiders 10.07%7 more rows
What does a 1 for 4 reverse stock split mean?
For example, in a 1:4 reverse split, the company would provide one new share for every four old shares. So if you owned 100 shares of a $10 stock and the company announced a 1:4 reverse split, you would own 25 shares trading at $40 per share.
What is a reverse split on stocks?
When a company completes a reverse stock split, each outstanding share of the company is converted into a fraction of a share. For example, if a company declares a one for ten reverse stock split, every ten shares that you own will be converted into a single share.
Who is the CEO of TNX-102?
CEO Seth Lederman said that the company was "surprised and disappointed" by the interim analysis findings. That's understandable, especially considering that TNX-102 SL met the primary endpoint of a previous late-stage study that was similar in design.
Why did Tonix stop the study?
The IDMC recommended stopping the study after concluding that TNX-102 SL was unlikely to demonstrate a statistically significant clinical improvement for patients with fibromyalgia.
What is TNX 102 SL?
TNX-102 SL is Tonix's lead pipeline candidate. In addition to being evaluated in treating fibromyalgia, the company also has hopes for the drug in treating post-traumatic stress disorder-related sleep disturbance, agitation in patients with Alzheimer's disease, and alcohol use disorder.
What is Tonix Pharmaceuticals?
Tonix Pharmaceuticals Holding Corp. engages in developing medicines for common disorders of the central nervous system. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. The company's lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of fibromyalgia; and Phase ... Read more
Is Tonix Pharmaceuticals Holding Corp. stock A Buy?
Tonix Pharmaceuticals Holding Corp. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
What is TNX-102 SL?
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102 SL tablet for the management of fibromyalgia. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. Data were presented at the 2021 American Society of Clinical Psychopharmacology Annual Meeting. The trial met its pre-specified primary endpoint with
What is the patent for Tonix?
Tonix announced that last Tuesday, it received a patent for "Trefoil Family Factor Proteins and Uses Thereof."
Who is the Motley Fool contributor for 2021?
In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss the best healthcare stocks that Robinhood investors like. Keith Speights: Robinhood stocks have just attracted a lot of attention in recent weeks and months.
When will Tonix start testing for PTSD?
Tonix previously noted that it may begin a late-stage study for PTSD in the first quarter of 2017. This remains a large risk, but there have effectively not been new treatments for PTSD for a decade and a half.
Is Tonix a late stage company?
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) was the disaster of the day on Tuesday after the company announced that it will stop development of its fibromyalgia treatment after it failed in a late-stage trial.